Regenerative cell therapy, using your own cells to treat osteoarthritis (OA), is a promising new paradigm of biologic treatment where your own body’s anti-inflammatory and repair properties of the cells and the growth factors present directly address the painful condition by facilitating healing. The therapy is safe and has provided assistance in reducing pain and improving mobility maintaining joint function in patients with OA of the knee, hip, shoulder, and ankle. Early clinical data suggests that regenerative treatments are shown to be effective in treating chronic tendon issues and regenerating articular cartilage in arthritic joints.
Adipose tissue (liposuction) derived mesenchymal stem cells (one of many forms of adult stem cells) show potential capability of regenerating or differentiating into cartilage, bone, and tendon tissue. The non-cultured forms also known as the Stromal Vascular Fractions (SVF), is the form that we are currently using. Similar applications are being used to treat patients with Platelet Rich Plasma (PRP).
PRP is a NICE (National Institute for Health and Clinical Excellence) recognised treatment covered by some NHS health authorities in the UK as well as Private Health Insurers for Osteoarthritis of the Knee. Mesenchymal stem cell treatment is still seen as “experimental” treatment by the insurers and at present is still not covered by the insurer.